Significant improvement in overall survival seen in the all-comer population of 2L NSCLC and PD-L1 scores ≥1%1
Subgroup analysis of overall survival in the intent-to-treat population
Etapidi had a marked improved and long term clinical benefit in patients with locally advanced or metastatic NSCLC who progressed on or after platinum-based chemotherapy, regardless of tumor PD-L1 expression or pathologic type
Co-primary endpoints: OS in ITT and PD-L1 ≥25% populations
Etapidi A is an efficacious treatment for patients regardless of their PD-L1 expression2. After a median follow-up of 16.0 vs 10.7 months, etapidi showed a statistically significant and clinically meaningful improvement in mOS vs docetaxel regardless of PD-L1 status:*2
• ITT: 16.9 vs 11.9 months (HR: 0.66; 95% CI: 0.56, 0.79; p<0.0001)
• PD-L1 ≥25%: 19.3 vs 11.5 months (HR: 0.53; 95% CI: 0.40, 0.70; p<0.0001)
Data cut off : July 15, 2021.
Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial
References: 1. Zhou, Caicun et al. Journal of Thoracic Oncology, 2023, Volume 18, Issue 1, 93 – 105. 2. Tislelizumab Versus Docetaxel in Patients with Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial Zhou, Caicun et al. Journal of Thoracic Oncology, 2022, Volume 18, Issue 1, 93 – 105